vs
Side-by-side financial comparison of Arch Capital Group (ACGL) and Becton Dickinson (BDX). Click either name above to swap in a different company.
Becton Dickinson is the larger business by last-quarter revenue ($5.3B vs $4.5B, roughly 1.2× Arch Capital Group). Arch Capital Group runs the higher net margin — 23.2% vs 7.3%, a 15.9% gap on every dollar of revenue. On growth, Becton Dickinson posted the faster year-over-year revenue change (-0.4% vs -3.3%). Over the past eight quarters, Arch Capital Group's revenue compounded faster (3.4% CAGR vs 2.0%).
Arch Capital Group Ltd. is a Bermuda exempted public company which writes insurance, reinsurance and mortgage insurance on a worldwide basis, with a focus on specialty lines, the segment of the insurance industry where the more difficult and unusual risks are written. The company is headquartered in Bermuda and operates globally in 60 offices in North America, Europe, Asia and Australia.
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
ACGL vs BDX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $5.3B |
| Net Profit | $1.0B | $382.0M |
| Gross Margin | — | 45.9% |
| Operating Margin | — | 10.5% |
| Net Margin | 23.2% | 7.3% |
| Revenue YoY | -3.3% | -0.4% |
| Net Profit YoY | 82.4% | 24.0% |
| EPS (diluted) | $2.88 | $1.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.5B | — | ||
| Q4 25 | $4.9B | $5.3B | ||
| Q3 25 | $5.1B | $5.9B | ||
| Q2 25 | $5.2B | $5.5B | ||
| Q1 25 | $4.7B | $5.3B | ||
| Q4 24 | $4.5B | $5.2B | ||
| Q3 24 | $4.7B | $5.4B | ||
| Q2 24 | $4.2B | $5.0B |
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.2B | $382.0M | ||
| Q3 25 | $1.4B | $493.0M | ||
| Q2 25 | $1.2B | $574.0M | ||
| Q1 25 | $574.0M | $308.0M | ||
| Q4 24 | $935.0M | $303.0M | ||
| Q3 24 | $988.0M | $400.0M | ||
| Q2 24 | $1.3B | $487.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | — | 47.8% | ||
| Q1 25 | — | 42.8% | ||
| Q4 24 | — | 43.2% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | 46.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 12.1% |
| Q1 26 | 23.2% | — | ||
| Q4 25 | 25.1% | 7.3% | ||
| Q3 25 | 26.4% | 8.4% | ||
| Q2 25 | 23.7% | 10.4% | ||
| Q1 25 | 12.3% | 5.8% | ||
| Q4 24 | 20.6% | 5.9% | ||
| Q3 24 | 20.9% | 7.4% | ||
| Q2 24 | 30.0% | 9.8% |
| Q1 26 | $2.88 | — | ||
| Q4 25 | $3.33 | $1.34 | ||
| Q3 25 | $3.56 | $1.71 | ||
| Q2 25 | $3.23 | $2.00 | ||
| Q1 25 | $1.48 | $1.07 | ||
| Q4 24 | $2.41 | $1.04 | ||
| Q3 24 | $2.56 | $1.37 | ||
| Q2 24 | $3.30 | $1.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.0M | $740.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $24.2B | $25.3B |
| Total Assets | $81.4B | $54.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $24.0M | — | ||
| Q4 25 | $993.0M | $740.0M | ||
| Q3 25 | $1.1B | $641.0M | ||
| Q2 25 | $983.0M | $735.0M | ||
| Q1 25 | $1.2B | $667.0M | ||
| Q4 24 | $979.0M | $711.0M | ||
| Q3 24 | $1.0B | $1.7B | ||
| Q2 24 | $1.0B | $4.5B |
| Q1 26 | $24.2B | — | ||
| Q4 25 | $24.2B | $25.3B | ||
| Q3 25 | $23.7B | $25.4B | ||
| Q2 25 | $23.0B | $25.5B | ||
| Q1 25 | $21.5B | $25.2B | ||
| Q4 24 | $20.8B | $25.2B | ||
| Q3 24 | $22.3B | $25.9B | ||
| Q2 24 | $20.7B | $25.9B |
| Q1 26 | $81.4B | — | ||
| Q4 25 | $79.2B | $54.8B | ||
| Q3 25 | $79.2B | $55.3B | ||
| Q2 25 | $78.8B | $54.9B | ||
| Q1 25 | $75.2B | $54.5B | ||
| Q4 24 | $70.9B | $54.7B | ||
| Q3 24 | $73.7B | $57.3B | ||
| Q2 24 | $65.5B | $55.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2B | $657.0M |
| Free Cash FlowOCF − Capex | — | $549.0M |
| FCF MarginFCF / Revenue | — | 10.5% |
| Capex IntensityCapex / Revenue | — | 2.1% |
| Cash ConversionOCF / Net Profit | 1.13× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.6B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.4B | $657.0M | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.5B | $164.0M | ||
| Q4 24 | $1.6B | $693.0M | ||
| Q3 24 | $2.0B | $1.2B | ||
| Q2 24 | $1.5B | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $549.0M | ||
| Q3 25 | $2.2B | $1.0B | ||
| Q2 25 | $1.1B | $1.0B | ||
| Q1 25 | $1.4B | $35.0M | ||
| Q4 24 | $1.6B | $588.0M | ||
| Q3 24 | $2.0B | $882.0M | ||
| Q2 24 | $1.5B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | 10.5% | ||
| Q3 25 | 42.6% | 17.0% | ||
| Q2 25 | 21.3% | 19.0% | ||
| Q1 25 | 31.0% | 0.7% | ||
| Q4 24 | 34.3% | 11.4% | ||
| Q3 24 | 42.5% | 16.2% | ||
| Q2 24 | 35.6% | 22.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.1% | ||
| Q3 25 | 0.2% | 6.0% | ||
| Q2 25 | 0.2% | 3.2% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.3% | 2.0% | ||
| Q3 24 | 0.3% | 5.4% | ||
| Q2 24 | 0.3% | 3.6% |
| Q1 26 | 1.13× | — | ||
| Q4 25 | 1.13× | 1.72× | ||
| Q3 25 | 1.62× | 2.75× | ||
| Q2 25 | 0.91× | 2.12× | ||
| Q1 25 | 2.54× | 0.53× | ||
| Q4 24 | 1.68× | 2.29× | ||
| Q3 24 | 2.04× | 2.94× | ||
| Q2 24 | 1.20× | 2.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACGL
Segment breakdown not available.
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
